The Syst-Eur trial is a multicentre, randomized, doublebelow 150 mm Hg. Matching placebos were employed similarly. The present progress report is based on the blind, placebo controlled therapeutical trial in patients at least 60 years old and with isolated systolic hypertendata received at the Coordinating Office before 1 March 1996. At that time 3433 subjects had been randomized. 
Introduction
strokes and severe arrhythmias in elderly hypertenIsolated systolic hypertension (ISH) is usually sive patients. 14 In most of these studies 10-14 the antidefined as a systolic blood pressure (SBP) of 160 hypertensive drug therapy reduced the risk of coronmm Hg or more in the presence of a diastolic blood ary events and overall mortality less than might be pressure (DBP) Ͻ90 or 95 mm Hg. In several studies, expected on the basis of non-interventional prospec-ISH in middle-aged and elderly people has been tive epidemiological studies. 15 shown to be associated with an increased cardioThe Systolic Hypertension in the Elderly Program vascular morbidity and mortality. [1] [2] [3] [4] [5] [6] [7] [8] [9] Since the num-(SHEP) trial, the first documentation of the prognosber of elderly people in European populations is tic value of antihypertensive drug therapy in elderly increasing rapidly and the prevalence of ISH persons with ISH, demonstrated that a diureticincreases steeply with age, the impact of ISH on the based treatment reduced non-fatal stroke, non-fatal well-being and survival of elderly people is of partimyocardial infarction and non-fatal congestive heart cular concern.
failure, but had no significant effect on fatal In elderly patients with combined systolic and events. 16 The patients in this trial were essentially diastolic hypertension (SDH) diuretics and betahealthy and represented only about 1% of the blockers have been shown to decrease cardiovascuscreened population. Therefore the generalizability lar events. [10] [11] [12] [13] In addition, results from the recent of the SHEP results has raised concern. 17 Shanghai trial of nifedipine in the elderly (STONE) The Systolic Hypertension in Europe (Syst-Eur) suggested for the first time that a calcium-antagonist, trial is being conducted to investigate the effect of antihypertensive drug treatment on the incidence of fatal and non-fatal strokes and overall cardiovascu- 2 statistic and the number of patients remaining on had been randomized. In this report we focus on the a given treatment by the log-rank statistic. changes in BP in the patients randomized to active or placebo treatment and assess the frequency of attaining goal SBP.
Results

Characteristics of the patients at randomization
On 1 March 1996, a total of 3433 patients from 11
Materials and methods
west European, 10 east European countries and Israel had been randomized into the Syst-Eur trial.
Study protocol
A total of 2015 patients, 971 patients in the placebo The main protocol of the Syst-Eur trial has been and 1044 in active treatment group, had been foldescribed in detail earlier. 18 Included in the study lowed for at least 1 year on double-blind treatment. are subjects of at least 60 years old, whose mean of A follow-up of at least 2 years on double-blind treatsix sitting BP values measured during a 3-month ment was attained by 1298 patients, 594 on placebo placebo run-in period was 160-219 mm Hg systolic treatment and 704 on active. The length of followand Ͻ95 mm Hg diastolic. The mean of six BP readup ranged from a few days to 7 years with a median ings in the standing position had to exceed 140 of 1 year. mm Hg. At randomization, the eligible patients were
The characteristics of the patients randomized in stratified by sex and the presence of possible cardiothe Syst-Eur trial, are given in Table 1 . At baseline vascular complications. The randomization to douthere were no significant differences between the ble-blind treatment was performed at the Coordinattwo treatment groups. Sixty-six per cent of the ing Office in Belgium. Active treatment consisted of patients were female. Mean age was 70 years (range nitrendipine 10-40 mg, if necessary, combined with 60-100 years). Thirty per cent of the participants enalapril 5-20 mg and hydrochlorothiatzide 12.5-had cardiovascular complications. Sitting BP at ran-25 mg per day. Matching placebo tablets were used domization was similar in men and women and in the control group. The goal was to lower the sitaveraged 174 mm Hg systolic and 86 mm Hg and 85 ting SBP by 20 mm Hg to 150 mm Hg or less by the mm Hg diastolic. Baseline SBP was higher in stepwise titration of double-blind medication. Durpatients previously treated with antihypertensive ing the double-blind period the patients were examdrugs (47%) than in previously untreated patients ined at 3-month intervals. Following randomization, (176 vs 173 mm Hg, P Ͻ 0.001). In contrast, baseline mortality and morbidity are monitored, but this DBP was 1 mm Hg lower in previously treated than analysis only deals with the effects of randomized in untreated patients (85 mm Hg vs 86 mm Hg, P Ͻ treatment on BP.
0.001). SBP was positively related to age (r = 0.15, P Ͻ 0.001), whereas DBP decreased with increasing age (r = −0.18, P Ͻ 0.001). Baseline DBP but not SBP was positively related to body mass index (r = 0.10, Analysis of BP measurements P Ͻ 0.001). Average BP at 1 year was calculated according to both a per-protocol and an intention-to-treat group reached the goal pressure (P Ͻ 0.001). At 2 years these proportions were 43% and 21% respect-
Patients not reaching goal pressure total (%)
ively (Tables 2 and 3 , Figure 2 ( Tables 2 and 3 ). a step 1 + 2 or step 2 drug only.
b step 1 + 2 + 3 or step 1 + 3 or step 2 + 3 or step 3 drug only.
Step 1 drug nitrendipine or placebo, step 2 drug enalapril or pla-
BP control
cebo, step 3 drug hydrochlorthiazide or placebo.
According to the per-protocol analysis, BP at 1 year averaged 152 ± 15/80 ± 9 mm Hg in the active treat- Values are numbers of patients (percentage given between parenthesis). a step 1 + 2 or step 2 drug only. b step 1 + 2 + 3 or step 1 + 3 or step 2 + 3 or step 3 drug only.
Step 1 nitrendipine or placebo, step 2 enalapril or placebo, step 3 hydrochlorthiazide or placebo.
± 19/84 ± 9 mm Hg in the placebo group (n = 1110). The reductions in BP from baseline were 22 ± 16/6 ± 8 mm Hg in the active treatment group and 12 ± 16/2 ± 8 mm Hg in the placebo group, respectively. At 1 year the difference in BP between the two treatment groups was 9.3 mm Hg systolic and 4.0 mm Hg diastolic (P Ͻ 0.001).
According to the per-protocol analysis at 2 years, BP decreased by 24 ± 16/7 ± 9 mm Hg in the active treatment group (n = 704) and by 12 ± 16/2 ± 8 mm Hg in the placebo group (n = 594) (P Ͻ 0.001). The difference in BP between the two treatment mm Hg in the active treatment group and by 13 ±
Discussion
In the intention-to-treat analysis of the Syst-Eur trial at 1 year, the decrease in SBP from baseline averaged 21.9 mm Hg in the active treatment group and 12.3 mm Hg in placebo group. Active treatment reduced DBP by 5.8 mm Hg while placebo administration was associated with a marginal 1.5 mm Hg though statistically significant decrease in DBP. At 2 years SBP decreased by 23.2 mm Hg in the active treatment group and by 12.7 mm Hg in the placebo group and DBP by 6.8 mm Hg and 2.2 mm Hg, respectively.
In the randomized stepped-care treatment programme of the SHEP trial the first-line active medication was chlorthalidone 12.5-25 mg/day and the second-line drug was atenolol 25-50 mg/day. In the presence of contraindications or side effects the lat- At baseline, SBP was 4 mm Hg and DBP 9 mm Hg higher in the Syst-Eur trial than in the SHEP trial. Also, throughout follow-up the average BP in the Syst-Eur trial was higher than in the SHEP trial (intention-to-treat analysis). At 2 years in the patients randomized to the active treatment the systolic/diastolic difference averaged 10/11 mm Hg, and in patients randomized to placebo 8/11 mm Hg. In the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) the differences between treatment groups at 1 and 2 years were 22/9 mm Hg and 22/10 mm Hg, 12 and in the European Working Party on High Blood Pressure in the Elderly trial (EWPHE) at 3 years 23/9 mm Hg in all hypertensive patients and 19/8 mm Hg in patients with ISH. 22 The changes in BP levels in different studies depend much on the inclusion criteria and the baseline BP values. Thus the changes are not directly comparable between studies.
In the SHEP trial, the goal BP was reached by 65-72% of the patients in the active treatment group cebo group. At 2 years these percentages were 43% and 21%, respectively.
Several factors may explain the differences in proportions of patients reaching the goal pressure between Syst-Eur and SHEP trials. First, the goal BP 18/2 ± 8 mm Hg in the placebo group. The difference in BP between the two treatment groups was 10/5 was differently defined in these trials. Second, in the SHEP trial a considerable number of patients were mm Hg (P Ͻ 0.001). Bojanova, D Bozhinov, ST Brayanova, MP Dabcheva, L Dimitrova, E Dimitrov, TI Draganov, A Elenprove the benefit of these drugs in terms of mortality and morbidity. Calcium antagonists have been suskova, R Eremieva, NB Ganov, SZ Georgiev, VI Gergova, AI Gogov, EG Goshev, M Grigorov, VS pected to be related to a gastrointestinal haemorrhage and cancer in elderly hypertensive persons Guidarsky, IG Ianev, K Jankulova, V Jordanova, DK Kamenova, R Kermova, L Koeva, Z Kuneva, GG Lazand to myocardial infarction and increased mortality in patients with coronary heart disease.
arova, E Lilov, E Lubenova, SI Mantov, T Marinova, R Mateva, AK Mihov, L Mitkova, C Nachev The report of the Joint National Committee V (JNC V) gave a clear preference to diuretics and beta-(Regional Coordinator), L Naidenova, N Nikolova, VN Nikolova, SV Obretenova, JS Panteva, V Pashblockers as initial drugs for antihypertensive therapy on the basis of well-documented efficacy of eva, A Petkov, PA Petrov, AL Popov, DG Popov, NS Popova, TR Poryasova, R Prokopova, LS Radeva, RV these drugs to reduce cardiovascular risk in controlled trials. 28 Also, the British Hypertension Radoeva, KN Ramshev, KJ Raykova, PB Rusafov, BE Shahov( †), Z Simeonova, V Sirakova, AT SlavtchSociety had recommended diuretics as the first-step treatment for hypertension in elderly patients. 29 A eva, DS Smilcova, P Solakov, A Spasova, M Staneva, ZM Stereva, V Stoyanovsky, T Tchernev, S Tisheva, single-blind, placebo-controlled STONE-trial has recently shown for the first time that the risk of car-KT Todorova, M Todorova, M Tzekova, I Tzenov, VH Vasilev, TN Vasileva, V Veselinov, A Volcov, K diovascular events, strokes and severe arrhythmias decreased in elderly Chinese patients with SDH Yablanski, YT Yotov, MA Zaprianova, R Zdravcova, Z Zozanov. treated with nifedipine.
14 At present, the Syst-Eurand Syst-China-trials 30 are the only on-going doubleCroatia: N Pivac, Z Rumboldt. Czechia: J Filipovsky. blind, placebo-controlled trials for treatment of ISH in elderly people, using as a first-step active treatEstonia: T Laks, T Podar, U Planken. Finland: J Airas, M Alaluoto, R Antikainen, T Hakament nitrendipine, a calcium channel blocker of the dihydropyridine group and as a second-step active mä ki, K Halonen, M Haapio, M Jä äskivi, S Junnila, E Karonen, P Kivinen, P Kohonen-Jalonen, P Kuusidrug an ACE-inhibitor. Both trials are placebo-controlled and monitor mortality and morbidity prosto, A Latva-Nevala, E Lehmus, E Lehtomä ki, A Lehtonen, R Ristolainen, E Ruotsalainen, C Sarti, R spectively.
Tilvis, J Tuomilehto (Regional Coordinator), H Vanhanen, O Vänskä, H Viitanen, M Viitaniemi, S Vinni S, H Wallinheimo.
